Ostarine would be the closest SARM to currently being authorized in drugs and is particularly at present in stage II medical trials. Like SARMs normally, MK-2866 targets androgen receptors on the selective basis and avoids making the sorts of damaging side effects related with substances like testosterone, human growth hormone, or anabolic steroids